Psychiatric and Medical Comorbidity in the Primary Care Geriatric Patient—An Update
- 443 Downloads
The mental health needs of older primary care patients are now widely recognized if not widely addressed. The range of behavioral health approaches including co-locating psychiatrists and integrating mental health professionals as care managers into primary care sites is extensive and growing. Nonetheless the primary care provider remains the first line of defense against mental disorders, most commonly depression and anxiety that accompany and exacerbate common physical conditions. The excess, potentially avoidable disability that results from comorbidity makes it imperative that early recognition and evidence based intervention occur. Multi-morbidity and polypharmacy make intervention a challenge. Psychotherapy can help overcome comorbidity depression however the most accessible intervention would be an antidepressant FDA approved for both anxiety and depressive disorders. For all these reasons, a focus on physical conditions most commonly associated with mental disorders can foster early recognition before the older patient’s care becomes overwhelmingly complicated.
KeywordsComorbidity Geriatric Depression Anxiety Dementia Neurocognitive
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Gary J. Kennedy receives royalties for Geriatric Depression; A Clinical Guide from The Guilford Press and has received an honorarium from PlatformQ Medical Education.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.••Gallo JJ, Hwang S, Joo JH, Bogner HR, Morales KH, Bruce ML, et al. Multimorbidity, depression, and mortality in primary care: randomized clinical trial of an evidence-based depression care management program on mortality risk. J Gen Intern Med. 2015. doi: 10.1007/s11606-015-3524-y. Data from large a, multi-site, primary care intervention trial demonstrated that a depression care management program countered the amplifying effect of increasing morbidity on mortality. All patients exhibited increasing rates of death as their rates of morbidity increased. Depressed patients in the usual care arm experienced substantially greater death rates than all others.
- 3.•Avari JN, Alexopoulos GS. Models of care for late-life depression of the medically ill: examples from chronic obstructive pulmonary disease and stroke. Am J Geriatr Psychiatry. 2015;23(5):477–87. The authors describe in detail the elements of psychotherapeutic interventions for depression specific to physical illnesses which may be acute or chronic. The approach is comprehensive yet pragmatic, representing anew that he psychosocial and biomedical determinants of health and well being cannot be separated.Google Scholar
- 10.Schüz N, Walters JA, Cameron-Tucker H, Scott J, Wood-Baker R, Walters EH. Patient anxiety and depression moderate the effects of increased self-management knowledge on physical activity: a secondary analysis of a randomised controlled trial on health-mentoring in COPD. COPD. 2015;12(5):502–9. doi: 10.3109/15412555.2014.995289.CrossRefPubMedGoogle Scholar
- 11.Borson S, Claypoole K, McDonald GJ. Depression and chronic obstructive pulmonary disease: treatment trials. Semin Clin Neuropsychiatry. 1998;2:115–30.Google Scholar
- 12.Kennedy GJ. Pharmacotherapy, in geriatric depression: a clinical guide. New York: The Guilford Press; 2015. p. 34–63.Google Scholar
- 16.••Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR. Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry. 2006;63(3):283–8. doi: 10.1001/archpsyc.63.3.283. This is a landmark study of pharmacologic intervention for depression following hospitalization for an acute coronary event. Prior episodes of depression and currently elevated level of severity predicted which patients would benefit for sertraline. Some have argued that patients hospitalized for an acute coronary event who have a prior history of major depression should receive prophylactic antidepressant treatment even is their level of symptoms do not reach criteria for a major depressive disorder.
- 17.Xiong GL, Prybol K, Boyle SH, Hall R, Streilein RD, Steffens DC, et al. Inflammation markers and major depressive disorder in patients with chronic heart failure: results from the sertraline against depression and heart disease in chronic heart failure study. Psychosom Med. 2015;77(7):808–15.CrossRefPubMedGoogle Scholar
- 18.Sokoreli I, de Vries JJ, Pauws SC, Steyerberg EW. Depression and anxiety as predictors of mortality among heart failure patients: systematic review and meta-analysis. Heart Fail Rev. 2015.Google Scholar
- 19.•Brouwers C, Christensen SB, Damen NL, Denollet J, Torp-Pedersen C, Gislason GH, et al. ntidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression. Int J Cardiol. 2015;203:867–73. This study and reference 20 are noteworthy for finding of no benefits form antidepressants among CHF patients. However the frequency with which antidepressants were prescribed without an accompanying documentation of a depressive disorder raises questions about the quality of the prescribing including indications, choice of medication, dose and duration of treatment.Google Scholar
- 20.•O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol. 2010;56(9):692–9. Carefully prescribed sertraline did not harm but did not benefit CHF patients with depression.Google Scholar
- 24.Scazufca M, Menezes P, Tabb K, Kester R, Rössler W, Huang H. Identification and treatment of depression of older adults in primary care: findings from the São Paulo ageing and health study. Fam Pract. 2015.Google Scholar
- 27.Stoop CH, Nefs G, Pommer AM, Pop VJ, Pouwer F. Effectiveness of a stepped care intervention for anxiety and depression in people with diabetes, asthma or COPD in primary care: a randomized controlled trial. J Affect Disord. 2015;184:269–76. doi: 10.1016/j.jad.2015.05.063.CrossRefPubMedGoogle Scholar
- 37.Hackett MI, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008. CD003437.Google Scholar
- 39.•Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, et al. Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy. J Neuropsychiatry Clin Neurosci. 2014;26(4):323–8. doi: 10.1176/appi.neuropsych.11020047. This study is another example of how antidepressant therapy needs to be coupled with disease specific psychotherapy in the context of multi-morbidity to achieve the desired results.
- 40.Kua J. The prevalence of psychological and psychiatric sequellae of cancer in the elderly—how much do we know? Ann Acad Med. 2005;34(3):250–6.Google Scholar
- 45.Heine C, Browning CJ. Mental health and dual sensory loss in older adults: a systematic review. Front Aging Neurosci. 2014;6(83):1–9.Google Scholar
- 46.Kiely KM, Anstey KJ, Luszcz MA. Dual sensory loss and depressive symptoms: the importance of hearing, daily functioning, and activity engagement. Front Hum Neurosci. 2013;7(837):1–13.Google Scholar
- 47.Court H, McLean G, Guthrie B, Mercer SW, Smith DJ. Visual impairment is associated with physical and mental comorbidities in older adults: a cross-sectional study. BMC Med. 2014;12(181):1–8.Google Scholar
- 49.Gall C, Brösel D, Sabel BA. Remaining visual field and preserved subjective visual functioning prevent mental distress in patients with visual field defects. Front Hum Neurosci. 2013;7(584):1–8.Google Scholar
- 50.•Rovner BW, Casten RJ, Hegel MT, Massof RW, Leiby BE, Ho AC, et al. Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2014;121(11):2204–11. In previous studies the authors were able to reduce the incidence of depression among persons visual impairment in one eye prior to the onset of impairment due to macular degeneration in the second eye.Google Scholar
- 54.Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3–5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendation by the European Renal Best Practices (ERBP). Nephrol Dial Transplant. 2012;27:3736–45.CrossRefPubMedGoogle Scholar
- 56.Gandhi R, Syweil MG, Mahomed NN, Perruccio AV. Depression and the overall burden of painful joints: an examination among oindiiviiduals undergoing hip and knee replacement for osteoarthritis. Arthritis 2015;327Google Scholar
- 60.Matcham F, Norton S, Scott DL, et al. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized trial. Rheumatology (Oxford) 2015.Google Scholar
- 64.Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72(02):126–33.CrossRefPubMedPubMedCentralGoogle Scholar
- 65.••Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache county study. Int J Geriat Psychiatry. 2008;23(2):170–7. The importance of this study is based on the highly representative character of the community-based sample as well as the analysis showing three clusters of neuropsychiatric symptoms.Google Scholar
- 71.Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012;69(5):493–8Google Scholar
- 73.•Hodgson NA, Gitlin LN, Winter L, Czekanski K. Undiagnosed illness and neuropsychiatric behaviors in community residing older adults with dementia. Alzheimer Dis Assoc Disord. 2011;25(2):109–15. This study is yet again a reminder that sudden change in mental status calls for a search for reversible cause most notably infection.Google Scholar
- 74.•Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatr AJP. 2012;169(9):946–53. Noteworthy review of risk and benefits of pharmacotherapy for neuropsychiatric symptoms of dementia.Google Scholar
- 75.Seitz DP, Brisbin S, Herrmann N, Rapoport MJ, Wilson K, Gill SS, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc. 2012:13 Suppl 6.Google Scholar
- 76.Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess. 2014;18(39):1–226. doi: 10.3310/hta18390. v-vi.CrossRefGoogle Scholar
- 79.Ballard CG. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2012.Google Scholar
- 81.•Porsteinsson AP Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, et al. Effect of citalopram on agitation in Alzheimer disease. JAMA. 2014;311(7):682. Important findings reinforce the dictum of when in doubt about what to prescribe an agitation choose an antidepressant. However the doses of citalopram employed in the study would be considered excessive under current guidelines.Google Scholar
- 83.•Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–54. doi: 10.1001/jama.2015.10214. Novel study design with intriguing findings that await replication.
- 87.•Blow FC, Barry K. Alcohol and substance misuse in older adults. Curr Psychiatry Rep. 2012;14(4):310–9. Highly pragmatic review of basic and more advanced interventions.Google Scholar
- 88.Rigler SK. Alcoholism in the elderly. Am Fam Physician. 2000;61 Suppl 6:1710–6, 1883–4, 1887–8 passim.Google Scholar